The Chinese University of Hong Kong

About: The Chinese University of Hong Kong is a education organization based out in Hong Kong, China. It is known for research contribution in the topics: Population & Computer science. The organization has 43411 authors who have published 93672 publications receiving 3066651 citations.

A Survey of Crowdsourcing Systems

Abstract: Crowd sourcing is evolving as a distributed problem-solving and business production model in recent years. In crowd sourcing paradigm, tasks are distributed to networked people to complete such that a company's production cost can be greatly reduced. In 2003, Luis von Ahn and his colleagues pioneered the concept of "human computation", which utilizes human abilities to perform computation tasks that are difficult for computers to process. Later, the term "crowdsourcing" was coined by Jeff Howe in 2006. Since then, a lot of work in crowd sourcing has focused on different aspects of crowd sourcing, such as computational techniques and performance analysis. In this paper, we give a survey on the literature on crowd sourcing which are categorized according to their applications, algorithms, performances and datasets. This paper provides a structured view of the research on crowd sourcing to date.

Development of the Chinese Personality Assessment Inventory

Abstract: A combined "emic-etic" approach was adopted to develop an indigenous omnibus personality inventory for the Chinese people. The Chinese Personality Assessment Inventory (CPAI) consists of constructs selected specifically in consideration of the Chinese culture as well as scales covering personality constructs commonly found in English-language psychological tests. Preliminary results confirmed the robust structure of the scales related to Chinese tradition among random samples of subjects in the People's Republic of China and in Hong Kong. This article reports the psychometric properties of the CPAI. It also outlines the steps in the construction of the CPAI, which adapted personality assessment methods used in Western countries for developing a culturally relevant instrument in a non-Western culture. The methodology provides an example for the development of indigenous personality inventories in other non-Western cultures.

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Abstract: Summary Background Ceritinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor, which has shown robust anti-tumour efficacy, along with intracranial activity, in patients with ALK -rearranged non-small-cell lung cancer. In phase 1 and 2 studies, ceritinib has been shown to be highly active in both ALK inhibitor-naive and ALK inhibitor-pretreated patients who had progressed after chemotherapy (mostly multiple lines). In this study, we compared the efficacy and safety of ceritinib versus single-agent chemotherapy in patients with advanced ALK -rearranged non-small-cell lung cancer who had previously progressed following crizotinib and platinum-based doublet chemotherapy. Methods In this randomised, controlled, open-label, phase 3 trial, we recruited patients aged at least 18 years with ALK -rearranged stage IIIB or IV non-small-cell lung cancer (with at least one measurable lesion) who had received previous chemotherapy (one or two lines, including a platinum doublet) and crizotinib and had subsequent disease progression, from 99 centres across 20 countries. Other inclusion criteria were a WHO performance status of 0–2, adequate organ function and laboratory test results, a life expectancy of at least 12 weeks, and having recovered from previous anticancer treatment-related toxicities. We randomly allocated patients (1:1; with blocking [block size of four]; stratified by WHO performance status [0 vs 1–2] and presence or absence of brain metastases) to oral ceritinib 750 mg per day fasted (in 21 day treatment cycles) or chemotherapy (intravenous pemetrexed 500 mg/m 2 or docetaxel 75 mg/m 2 [investigator choice], every 21 days). Patients who discontinued chemotherapy because of progressive disease could cross over to the ceritinib group. The primary endpoint was progression-free survival, assessed by a masked independent review committee using Response Evaluation Criteria in Solid Tumors 1.1 in the intention-to-treat population, assessed every 6 weeks until month 18 and every 9 weeks thereafter. This trial is registered with ClinicalTrials.gov, number NCT01828112, and is ongoing but no longer recruiting patients. Findings Between June 28, 2013, and Nov 2, 2015, we randomly allocated 231 patients; 115 (50%) to ceritinib and 116 (50%) to chemotherapy (40 [34%] to pemetrexed, 73 [63%] to docetaxel, and three [3%] discontinued before receiving treatment). Median follow-up was 16·5 months (IQR 11·5–21·4). Ceritinib showed a significant improvement in median progression-free survival compared with chemotherapy (5·4 months [95% CI 4·1–6·9] for ceritinib vs 1·6 months [1·4–2·8] for chemotherapy; hazard ratio 0·49 [0·36–0·67]; p vs 12 [11%] in the chemotherapy group). The most frequent grade 3–4 adverse events in the ceritinib group were increased alanine aminotransferase concentration (24 [21%] of 115 vs two [2%] of 113 in the chemotherapy group), increased γ glutamyltransferase concentration (24 [21%] vs one [1%]), and increased aspartate aminotransferase concentration (16 [14%] vs one [1%] in the chemotherapy group). Six (5%) of 115 patients in the ceritinib group discontinued because of adverse events compared with eight (7%) of 116 in the chemotherapy group. 15 (13%) of 115 patients in the ceritinib group and five (4%) of 113 in the chemotherapy group died during the treatment period (from the day of the first dose of study treatment to 30 days after the final dose). 13 (87%) of the 15 patients who died in the ceritinib group died because of disease progression and two (13%) died because of an adverse event (one [7%] cerebrovascular accident and one [7%] respiratory failure); neither of these deaths were considered by the investigator to be treatment related. The five (4%) deaths in the chemotherapy group were all due to disease progression. Interpretation These findings show that patients derive significant clinical benefit from a more potent ALK inhibitor after failure of crizotinib, and establish ceritinib as a more efficacious treatment option compared with chemotherapy in this patient population. Funding Novartis Pharmaceuticals Corporation.

Detect Rumors in Microblog Posts Using Propagation Structure via Kernel Learning

Abstract: How fake news goes viral via social media? How does its propagation pattern differ from real stories? In this paper, we attempt to address the problem of identifying rumors, i.e., fake information, out of microblog posts based on their propagation structure. We firstly model microblog posts diffusion with propagation trees, which provide valuable clues on how an original message is transmitted and developed over time. We then propose a kernel-based method called Propagation Tree Kernel, which captures high-order patterns differentiating different types of rumors by evaluating the similarities between their propagation tree structures. Experimental results on two real-world datasets demonstrate that the proposed kernel-based approach can detect rumors more quickly and accurately than state-of-the-art rumor detection models.

Approximate Computing: A Survey

Abstract: As one of the most promising energy-efficient computing paradigms, approximate computing has gained a lot of research attention in the past few years. This paper presents a survey of state-of-the-art work in all aspects of approximate computing and highlights future research challenges in this field.